Journal for ImmunoTherapy of Cancer · 2022 · 15 citations · 12 references
Life SciencesImmunologyOncologyCancer ImmunologyImmunotherapyTumor ImmunologyBiomarker-guided ImmunotherapyCancer ImmunotherapyCheckpoint Inhibitor TherapyImmune Checkpoint InhibitorsImmuno-oncology BiomarkersMelanoma PharmacotherapyImmune Biomarker ProfilingImmune Biomarkers In CancerImmune Checkpoint Inhibitor BiomarkersMelanoma BiomarkersMelanoma ImmunotherapyMetastatic Melanoma TreatmentPatient Outcomes MeasurementTreatment Response Biomarkers
BACKGROUND: Nivolumab is an anti-PD-1 antibody approved for treating metastatic melanoma (MM), for which still limited evidence is available on the correlation between drug exposure and patient outcomes. METHODS: In this observational retrospective study, we assessed whether nivolumab concentration is associated with treatment response in 88 patients with MM and if the patient's genetic profile plays a role in this association. RESULTS: We observed a statistically significant correlation between nivolumab serum concentration and clinical outcomes, measured as overall and progression-free survival. Moreover, patients who achieved a clinical or partial response tended to have higher levels of nivolumab than those who reached stable disease or had disease progression. However, the difference was not statistically significant. In particular, patients who reached a clinical response had a significantly higher concentration of nivolumab and presented a distinct genetic signature, with more marked activation of ICOS and other genes involved in effector T-cells mediated proinflammatory pathways. CONCLUSIONS: In conclusion, these preliminary results show that in patients with MM, nivolumab concentration correlates with clinical outcomes and is associated with an increased expression of ICOS and other genes involved in the activation of T effectors cells.
12
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer et al. · New England Journal of Medicine · 2012 · 12.7K citations · Full text
Life Sciences, Immunology, Oncology +17
Paolo A. Ascierto, Michele Del Vecchio, Mario Mandalà et al. · The Lancet Oncology · 2020 · 525 citations
Medicine, Immunology, Oncology +17
James Larkin, David R. Minor, Sandra P. D’Angelo et al. · Journal of Clinical Oncology · 2017 · 510 citations · Full text
Medicine, Oncology, Pharmacology +17